CORRECTION





Correction to: Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in *TP*53-deficient cancer cells

Alicja Sznarkowska¹, Anna Kostecka¹, Anna Kawiak¹, Pilar Acedo², Mattia Lion^{3,4}, Alberto Inga³ and Joanna Zawacka-Pankau^{2*}

Correction to: Cell Div (2018) 13:10

https://doi.org/10.1186/s13008-018-0043-3 The authors note a correction to the article [1]. Figure 1d of the original article has an error. The pcDNA3/Ctrl and the pcDNA3-TAp73a/DMSO wells are duplicated. This article presents the corrected version of Fig. 1.

*Correspondence: joannazawackapankau1@gmail.com

² Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65 Stockholm, Sweden Full list of author information is available at the end of the article



© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



Fig. 1 PplX inhibits proliferation of cancer cells lacking p53. **a** Schematic representation of the splice variants in TP73 gene (upper panel) and domain structure of p73 (lower panel). *TA* transactivation domain, *DBD* DNA binding domain, *OD* oligomerization domain, *CTC* terminus. **b** PplX induces dose-dependent growth inhibition in a long-term proliferation assay. **c** Ectopic expression of TAp73α sensitizes cells to PplX after 24 h as demonstrated by WST-1 proliferation assay. Inserted blot represents the level of expression of TAp73α. Please note that the blot has been cropped. Dotted line represents where the blot has been cut. The uncropped full length version is presented in Additional file 3: Figure S3a. **d** TAp73α overexpression sensitizes H1299 to PplX-induced inhibition of proliferation. **e**, **f** PplX does not induce DNA damage in cancer cells at the effective therapeutic concentrations. **g** 2.5 µg/ml PplX induces PARP-1 cleavage in HCT 116 p53–/– but not in non-transformed human diploid fibroblasts. Dotted line represents where the blot has been cut. The uncropped blot is presented in Additional file 3: Figure S3b

Author details

¹ Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland. ² Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65 Stockholm, Sweden. ³ Centre for Integrative Biology, CIBIO, University of Trento, via Sommarive 9, 38123 Trento, Italy. ⁴ Present Address: Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Published online: 29 August 2019

The original article can be found online at https://doi.org/10.1186/s1300 8-018-0043-3.

Reference

 Sznarkowska A, Kostecka A, Kawiak A, Acedo P, Lion M, Inga A, Zawacka-Pankau J. Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in *TP*53deficient cancer cells. Cell Div. 2018;13:10. https://doi.org/10.1186/s1300 8-018-0043-3.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

